KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Total Current Liabilities: 2009-2024

Historic Total Current Liabilities for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $1.2 billion.

  • Novavax's Total Current Liabilities fell 63.60% to $429.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $429.9 million, marking a year-over-year decrease of 63.60%. This contributed to the annual value of $1.2 billion for FY2024, which is 29.40% down from last year.
  • According to the latest figures from FY2024, Novavax's Total Current Liabilities is $1.2 billion, which was down 29.40% from $1.6 billion recorded in FY2023.
  • Novavax's Total Current Liabilities' 5-year high stood at $2.5 billion during FY2022, with a 5-year trough of $579.7 million in FY2020.
  • In the last 3 years, Novavax's Total Current Liabilities had a median value of $1.6 billion in 2023 and averaged $1.7 billion.
  • Per our database at Business Quant, Novavax's Total Current Liabilities surged by 2,147.23% in 2020 and then crashed by 33.53% in 2023.
  • Over the past 5 years, Novavax's Total Current Liabilities (Yearly) stood at $579.7 million in 2020, then surged by 312.36% to $2.4 billion in 2021, then rose by 2.91% to $2.5 billion in 2022, then tumbled by 33.53% to $1.6 billion in 2023, then dropped by 29.40% to $1.2 billion in 2024.